Upstream Bio, Inc. - 8-K Filing

Upstream Bio reports Q3 2026 net loss of $41.2 million and plans Phase 3 trials for severe asthma and CRSwNP in Q1 2027. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 10, 2026, 12:05 UTC

Tickers: $UPB

Read the full article at SEC EDGAR

Part of the story Gossamer Bio, Inc. - 8-K Filing (13 articles)

More Regulatory news

Carter Bankshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:12 UTC
Marvell Technology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
VISHAY INTERTECHNOLOGY INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
LATTICE SEMICONDUCTOR CORP - 4 Filing SEC EDGAR · November 12, 2026, 14:10 UTC
CENTRUS ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:09 UTC
SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC